Stock TLX TELIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Delayed Australian S.E.
Other stock markets
 09:03:02 2024-07-07 pm EDT 		5-day change 1st Jan Change
18.39 AUD -0.49% Intraday chart for Telix Pharmaceuticals Limited +1.77% +82.64%
Jun. 06 Telix Pharmaceuticals Launches $200 Million IPO in US MT
Jun. 06 Telix Pharmaceuticals Launches $200 Million US IPO MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Telix Pharmaceuticals Launches $200 Million IPO in US
MT
Telix Pharmaceuticals Launches $200 Million US IPO
MT
Telix Announces Launch of Proposed Initial Public Offering in the United States
AQ
Telix Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy
MT
Telix Pharmaceuticals Completes US FDA Regulatory Submission for Kidney Cancer Imaging Agent
MT
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
AQ
Telix Pharma Reports Positive Data from Clinical Study of Prostate Cancer Drug; Shares Surge 15%
MT
Commodity, banking stocks help Australian shares snap 3-day slide
RE
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
AQ
Telix Submits NDA for New Prostate Cancer Imaging Agent
AQ
Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA
MT
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent
CI
Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug
MT
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
AQ
Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO
MT
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
AQ
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.
CI
Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP
MT
Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLX Stock
  4. News Telix Pharmaceuticals Limited